| Methods |
RCT.
Open label.
Active controlled. |
| Participants |
47 participants with newly diagnosed OAG or OHT.
50% of participants included with both eyes (mean of both eyes).
6/24 timolol and 8/23 epinephrine patients were African American.
Inclusion criteria: normal Goldmann visual fields and either 1) IOP between 25 and 29 mmHg and wide disc cupping or cupping asymmetry, or 2) IOP between 30 and 35 mmHg with normal optic discs.
Exclusion criteria: ocular inflammation, recent ocular surgery or trauma, previous glaucoma therapy. |
| Interventions |
Timolol 0.5% twice daily.
Epinephrine 1% twice daily |
| Outcomes |
Incidence of optic cup enlargement or disc haemorrhage (stereophoto).
Incidence of reproducible visual field defect.
Incidence of failure to achieve an IOP reduction of 20%. |
| Notes |
Mean follow up 33 months.
Failures were analysed on patient basis.
No drop‐outs, but 18 IOP failures: 7 timolol group, 11 epinephrine group. 5 patients originally assigned to timolol group (1 topical and 4 systemic side effects), and 4 patients of the epinephrine group (local or systemic side effects) switched the group. For failure analysis they were analysed in their original group (intent to treat). |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Low risk |
A ‐ Adequate |
